Benefits and Risks of Fosaprepitant in Patients Receiving Emetogenic Regimens.
Fosaprepitant dimeglumine (Emend IV®) is an IV antiemetic that may be beneficial to patients receiving highly emetogenic regimens. Aprepitant (Emend®) is an oral medication that is administered for three consecutive days, whereas fosaprepitant is a single-dose IV medication that is administered on the day of chemotherapy for 20-30 minutes (depending on the IV access type). Fosaprepitant may be useful, yet it can also present a risk for hypersensitivity reactions and phlebitis. Oncology nurses must be aware of the signs and symptoms of these potential adverse events to properly care for their patients.
Memorial Sloan Kettering Cancer Center.
Wendy
W
Pritchett
Memorial Sloan Kettering Cancer Center.
Karen
K
Kinsley
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000932:Antiemetics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000627:therapeutic use*; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy*; D009369:Neoplasms / Q000188:drug therapy*; D018570:Risk Assessment; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy*
D000932:Antiemetics; D000970:Antineoplastic Agents; D009025:Morpholines; C579707:fosaprepitant
antiemetic; hypersensitivity reaction; infusion site reaction; phlebitis
Support Care Cancer. 2014 Jun;22(6):1461-6
24402412
J Cancer. 2014 Apr 24;5(5):390-7
24799957
Anesth Analg. 2007 May;104(5):1082-9, tables of contents
17456656
Expert Opin Drug Metab Toxicol. 2010 Oct;6(10):1277-86
20795794
Support Care Cancer. 2014 May;22(5):1313-7
24402411
J Eval Clin Pract. 2014 Apr;20(2):191-202
24401116